Tulburări metabolice ale funcției hepatice la pacienți cu obezitate în contextul infecției COVID-19
Keywords:
COVID-19 virus infection, obesity, BMI, cytolysis syndrome, protein metabolism, albumin, Ferritin, C-reactive proteinAbstract
Pandemia COVID-19 și consecințele ei reprezintă o amenințare gravă asupra viața și sănătatea oamenilor, ducând la morbiditate, dizabilitate și mortalitate ridicate. Obezitatea și alte componente ale sindromului metabolic pot agrava decursul infecției cu COVID-19 și starea funcțională a sistemului hepatobiliar. Scopul studiului a fost studierea parametrilor biochimici care caracterizează sindromul de citoliză și metabolismul proteic la pacienții obezi cu infecție virală SARS CoV-2. Am examinat 44 de pacienți: 27 bărbați (61,6%), 17 femei (38,6%). Vârsta medie a constituit 55,16 ± 4,5 de ani. Pacienții au fost împărțiți în 4 grupe: grupul 1 (9) a fost format din pacienți cu un indice de masă corporală (IMC) de 30, grupul 2 (8) cu un IMC de 35, grupul 3 cu un IMC de 40, grupul 4 de comparație (GC) a constat din pacienți (17) fără semne de obezitate. La toți pacienții au fost studiate sindromul de citoliză (ALAT, ASAT) și metabolismul proteic: feritina (FT), albumina serică și proteina C reactivă (CRP). Studiul a evidențiat o creștere a nivelurilor de ALAT, ASAT, FT și CRP la pacienții cu un indice de masă corporal ridicat pe fondul scăderii albuminei serice. Toți pacienții cu infecție virală COVID-19 și obezitate au prezentat modificări în parametrii sindromului de citoliză și metabolismului proteic. Pacienții cu infecție virală COVID-19 și obezitate constituie un grup cu risc ridicat și necesită monitorizare preventivă și diagnostic constantă de către gastroenterologi și endocrinologi.
References
1. Banchini, F., Cattaneo, G.M., Capelli, P. Serum ferritin levels in inflammation: a retrospective comparative analysis between COVID-19 and emergency surgical non-COVID-19 patients. In: World J Emerg Surg. 2021; 16:9. https://doi.org/10.1186/s13017-021-00354-3
2. Baral, R., Ali, O., Brett, I., Reinhold, J., Vassiliou, V.S. COVID-19: a pan-organ pandemic. In: Oxf Med Case Reports. 2020. https://doi.org/10.1093/omcr/omaa107
3. Beyerstedt, S., Casaro, E.B., Rangel, É.B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. In: Eur J ClinMicrobiol Infect Dis. 2021; 40, pp. 905-919. https://doi.org/10.1007/s10096-020-04138-6
4. Black, S., Kushner, I., Samols, D. C-reactive protein. In: JBiol Chem. 2004; 279(47), pp. 48487-48490. https://doi.org/10.1074/jbc.R400025200
5. Booth, A., Magnuson, A., Fouts, J., Foster, M.T. Adipose tissue: an endocrine organ playing a role in metabolic regulation. In: HormMolBiolClin Invest. 2016; 26(1), pp. 25-42. https://doi.org/10.1515/hmbci-2015-0073
6. Chen, J., Chen, J., Fu, H., Li, Y., Wang, L., Luo, S., Lu, H. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. In: Am J PhysiolEndocrinolMetab.2019; 317, pp. E710-E722. https://doi.org/10.1152/ajpendo.00052.2019
7. Chen, L., Liu, H.G., Liu, W., Liu, J., Liu, K., Shang, J. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. In: ZhonghuaJie He He Hu Xi ZaZhi. 2020; 43(3), pp. 203-208.
8. Cheung, K.S., Hung, I.F.N., Chan, P.P.Y., Lung, K.C., et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and metaanalysis. In: Gastroenterology. 2020; 159(1), pp. 81-95. https://doi.org/10.1053/j.gastro.2020.03.065
9. Chinazzi, M., Davis, J.T., Ajelli, M., Gioannini, C., Litvinova, M., Merler, S., et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. In: Science. 2020; 368(6489), pp. 395-400. https://doi.org/10.1126/science.aba9757
10. Curocichin, Gh., Șalaru, V., Gîțu, L. Protocolul clinic standardizet pentru medicii de familie. Infecția cu coronavirus de tip nou COVID-19. Pentru aplicare în cazul de sfășurării Scenariului 3 din Planul de pregătire și răspuns, la infecţia cu coronavirus de tip nou COVID-19. Chișinău, 2020; 6 p.
11. Da, BL., Mitchell, RA., Lee, BT., et al. Kinetic patterns of liver enzyme elevation with COVID-19 in the USA. In: Eur. GastroenterolHepatol. 2020; 32(11), pp. 1466-1469. https://doi.org/10.1097/MEG.0000000000001792
12. Dalan, R., Bornstein, S.R., El-Armouche, A., Rodionov, R.N., Markov, A., Wielockx, B. The ACE-2 in COVID-19: foe or friend? In: HormMetab Res. 2020; 52(5), pp. 257-263. https://doi.org/10.1055/a-1155-0501
13. Di Angelantonio, E., Bhupathiraju, Sh. N., Wormser, D., Gao, P., Kaptoge, S., et al. Global BMIMC, Body-mass index and all-cause mortality: individual-participantdata meta-analysis of 239 prospective studies in four continents. In: Lancet. 2016; 388, pp. 776-786.
14. Garcia, L.F. Immune response, inflammation, and the clinical Spectrum of COVID-19. In: Front Immunol. 2020; 11, pp. 1441. https://doi.org/10.3389/fimmu.2020.01441
15. Gupte, M., Thatcher, S.E., Boustany-Kari, C.M. et al Angiotensin converting enzyme 2 contributes to sex differences in the development of obesity hypertension in C57BL/6 mice. In: ArteriosclerThrombVascBiol .2012 32, pp. 1392-1399. https://doi.org/10.1161/ATVBAHA.112.248559
16. Hamid. S, Alvares da Silva, M.R., Burak, K.W., Chen, T, Drenth, J.P.H., Esmat, G., Gaspar, R., La Brecque, D., Lee, A. , Macedo, G., McMahon, B., Ning, Q., Reau, N., Sonderup, M., van Leeuwen, DJ., Armstrong, D., Yurdaydin, C. WGO guidance for the care of patients with covid-19 and liver disease. In: J ClinGastroenterol. 2021; 55, pp.1-11. https://doi.org/10.1097/MCG.0000000000001459
17. Huang, W., Li, C., Wang, Z., et al. Decreased serum albumin level indicates poor prognosis of Covid-19 patients: hepatic injury analysis from 2623 hospitalized cases. In:Sci China Life Sci. 2020; 63(11), pp. 1678-1687. https://doi.org/10.1007/s11427-020-1733-4
18. Lefere, S., Tacke, F. Macrophages in obesity and nonalcoholic fatty liver disease: Crosstalk with metabolism. In: JHEP Rep.2019; 1, pp. 30-43. https://doi.org/10.1016/j.jhepr.2019.02.004
19. Li, R., Liangm M., Diang, J. Liver injury in COVID-19 patients with metabolic syndrome a narrative rewiew. In: Ann Paliliat Med 2021; 10(7), pp. 8264-8270. https://doi.org/10.21037/apm-21-1398
20. Liu, R., Nikolajczyk, B.S. Tissue immune cells fuel obesity-associated inflammation in adipose tissue and beyond. In: Front Immunol. 2019; 10, pp. 1587. https://doi.org/10.3389/fimmu.2019.01587
21. Lupasko I., Ghelmici T., Berezovscaia E., Golovatiuc L., Bugor K., Burda T. Assessment of Liver Function in SARS-CoV-2 Viral Infection. In: report during the Conference 3 Eurasian Conference The Coronovirus Pandemic; Diagnosis, Treatment 27-28 April. 2022 Bacu.
22. Lupașco, I., Tcaciuc, E., Dumbrava, V.-T., Vengher, I., Taran, N., Berezovscaia, E. Ghid de conduită a pacienților cu boli crоnice difuze hepatice în condiții de pandemie cu Covid-19. Edițiaa II-a. Chișinău: CEP Medicina, 2022; 130 p. ISBN 978-9975-82-243-5.
23. Mehta, P., Cron, R.Q., Hartwell, J., Manson, J.J., Tattersall, R.S. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocyticlymphohistiocytosis or macrophage activation syndrome. In: Lancet Rheumatol. 2020; 2, pp. e358-367. https://doi.org/10.1016/S2665-9913(20)30096-5
24. Mehta, P., McAuley, D.F., Brown, M., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. In: Lancet. 2020; Mar.28, 395(10229), pp. 1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
25. Mostaghim, A., Sinha, P., Bielick, C. et al Clinical outcomes and inflammatory marker levels in patients with COVID-19 and obesity at an inner-city safety net hospital. In: PLoS ONE, 2020; nr. 15, e0243888. https://doi.org/10.1371/journal.pone.0243888
26. Petrilli, C.M., Jones, S.A., Yang, J., Rajagopalan, H., O'Donnell, L., Chernyak, Y., Tobin, K.A., Cerfolio, R.J., Francois, F., Horwitz, L.I. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. In: BMJ. 2020; 369, m1966. https://doi.org/10.1136/bmj.m1966
27. Plays, M., Müller, S., Rodriguez, R. Chemistry and biology of ferritin. In: Metallomics. 2021. https://doi.org/10.1093/mtomcs/mfab021
28. Rajgor, D.D., Lee, M.H., Archuleta, S., Bagdasarian, N., Quek, S.C. The many estimates of the COVID-19 case fatality rate. In: Lancet Infect Dis. 2020; 20(7), pp. 776-777. https://doi.org/10.1016/S1473-3099(20)30244-9
29. Richardson, S., Hirsch, J.S., Narasimhan, M., Crawford, JM., McGinn, T., Davidson, K.W., et al. Present ing characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. In: JAMA. 2020; 323(20), pp. 2052-2059. https://doi.org/10.1001/jama.2020.6775
30. Ryan, P.M., Caplice, N.M. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in Coronavirus disease 2019; In: Obesity.2020; nr. 28, pp. 1191-1194. https://doi.org/10.1002/oby.22843
31. Sachdeva, S., Khandait, H., Kopel, J., Aloysius, M.M., Desai, R., Goyal, H. NAFLD and COVID-19: a Pooled Analysis. In: ComprClin Med. 2020; pp.1-4. https://doi.org/10.1007/s42399-020-00631-3
32. Sajjad, V-S., Jalil, AT., Abdelbasset, WK.,Yumashev, A.V, Karpisheh, V., Jalali, P., Adibfar, S., Ahmadi, M., Feizi, A.A.H., Jadidi-Niaragh, F. Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies. In: DNA Repair. 2021.
33. Sattar, N., McInnes, I.B., McMurray, J.J.V. Obesity a risk factor for severe COVID-19 infection: multiple potential mechanisms. In: Circulation. 2020; 142(1), pp. 4-6. https://doi.org/10.1161/CIRCULATIONAHA.120.047659
34. Schipper, H.S., Prakken, B., Kalkhoven, E., Boes, M. Adipose tissue-resident immune cells: key players in immunometabolism. In: Trends EndocrinolMetab. 2012; nr. 23(8), pp. 407-415. https://doi.org/10.1016/j.tem.2012.05.011
35. Simonnet, A., Chetboun, M., Poissy, J., Raverdy, V., Noulette, J., Duhamel, A. et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. In: Obesity. 2020; nr. 28, pp.1195-1199. 36. Sudhakar, M., Silambanan, S., Chandran, A.S., et al. C - Reactive Protein (CRP) and leptin receptor in obesity: binding of monomeric CRP to leptin receptor. In: Front Immunol .2018; nr.9, pp. 1167. https://doi.org/10.1002/oby.22831
37. Vaughan, C.J., Cronin, H., Ryan, P.M., Caplice, N.M. Obesity and COVID-19: a Virchow's triad for the 21st century. In: ThrombHaemost. 2020; nr. 120(11), pp.1590-1593. 38. WHO. Obesity and Overweight. 2018. https://doi.org/10.1055/s-0040-1714216
39. Williamson, E.J., Walker, A.J., Bhaskaran, K., et al Factors associated with COVID-19-related death using OpenSAFELY. In: Nature. 2020; 584, pp. 430-436. https://doi.org/10.1038/s41586-020-2521-4
40. Xu,Y., Yang, H., Wang, J., Li, X, Xue, C., Niu, C. and Liao, P. Serum albumin levels are a predictor of COVID-19 patient prognosis: evidence from a single cohort in Chongqing, China. In: International Journal of General Medicine. 2021; nr. 14, pp. 2785-2797. https://doi.org/10.2147/IJGM.S312521
41. Xu, L., Liu, J., Lu, M., Yang, D., Zheng, X. Liver injury during highly pathogenic human coronavirus infections. In: Liver Int. 2020; nr. 40, pp. 998-1004. https://doi.org/10.1111/liv.14435
42. Zhang, Y., Zheng, L., Liu, L., Zhao, M., Xiao, J., Zhao, Q. Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. In: Liver Int. 2020; nr. 40, pp. 2095-2103. https://doi.org/10.1111/liv.14455
43. Zheng, K.I., Gao, F., Wang X.B., Sun, Q.F., Pan K.H., Wang, T.Y., et al. Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease. In: Metabolism.2020; nr. 108, 154244. https://doi.org/10.1016/j.metabol.2020.154244
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
